The success of Vertex's opioid alternative Journavx could aid a group of biotechs that aim to take a similar path with NaV1.8 ...

Company executives had seen the drug as a potential multi-billion dollar opportunity in women’s health.

The acquisition will expand AbbVie's exploration of in vivo CAR-T therapy, an ambitious approach that could sidestep some of ...

The brain drug developer is now saying that its two marketed products could ultimately bring in $2 billion annually, and its ...

The Trump administration aims to issue a rule empowering regulators to “forcefully” go after companies that don’t share drug ...

New members of the ACIP panel raised questions about the evidence supporting COVID vaccines, and signaled plans to look at ...

The biotech, which agreed to be bought by Supernus after clinical and commercial struggles, plans to lay off 338 employees by ...

New study results position Nuvalent to bring forward what it claims is a differentiated treatment for ROS1-positive lung ...

The agency removed some onerous requirements for the complex cancer drugs and reduced restrictions on patients’ ...

Bill Meury, who shepherded Karuna and Anthos to multibillion-dollar buyouts, will take over Incyte, a successful drug ...

Many proposals to reform the PBM industry miss the forest for the trees, experts said this week. Instead, Congress should go ...

Backed by Perceptive Xontogeny Venture Funds and venBio Partners, the new biotech will make genetic medicines that don’t rely ...